ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Erlotinib hydrochloride

Erlotinib hydrochloride

Erlotinib hydrochloride Suppliers list
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:Erlotinib hydrochloride
CAS:183319-69-9
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Erlotinib hydrochloride
CAS:183319-69-9
Purity:99% Package:8800/KG
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Erlotinib hydrochloride
CAS:183319-69-9
Company Name: Beijing Lunarsun Pharmaceutical Co.,LTD.  Gold
Tel:86-10-64911848-8020.8010
Email:sales@lunarsun.com.cn
Products Intro:Product Name:Erlotinib hydrochloride
CAS:183319-69-9
Purity:99% Package:On Request
Company Name: Dragon Fly INDUSTRY INT'L CO  Gold
Tel:15065329263
Email:info@goldenpromiseindustry.com
Products Intro:Product Name:Erlotinib hydrochloride
CAS:183319-69-9
Purity:99.00%
Erlotinib hydrochloride Basic information
Indications and Usage Mechanisms of Action Clinical Research
Product Name:Erlotinib hydrochloride
Synonyms:ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva; N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva Hydrochloride See E625000
CAS:183319-69-9
MF:C22H24ClN3O4
MW:429.9
EINECS:
Product Categories:API;Molecular Targeted Antineoplastic;Heterocyclic Compounds;anti-neoplastic;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tarceva;Antineoplastic;Anti-cancer&immunity;Inhibitors
Mol File:183319-69-9.mol
Erlotinib hydrochloride Structure
Erlotinib hydrochloride Chemical Properties
Melting point 223-225°C
storage temp. -20°C Freezer
CAS DataBase Reference183319-69-9(CAS DataBase Reference)
Safety Information
MSDS Information
Erlotinib hydrochloride Usage And Synthesis
Indications and UsageErlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.
It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment.
Mechanisms of ActionThe small molecular compound erlotinib is a tyrosine kinase receptor inhibitor which inhibits the proliferation of tumor cells by inhibiting phosphorylation, binding to the intracellular catalytic domain of tyrosine kinase in competition with ATP, thus blocking downstream signal transduction and inhibiting activity of tumor cell ligand dependent HER-1/EGFR.
Clinical ResearchPhase I clinical trials showed that the main toxicities and side effects of erlotinib were dose-dependent rashes and diarrhea. Other rare side effects included headaches, nausea, and vomiting. Phase II trials used erlotinib as a second-line anticancer drug, with efficacy matching second-line chemotherapy drug docetaxel. Phase III randomized control trials (BR21) mainly focused on NSCLC patients (locally advanced and distant metastasis) after the failure of first- or second-line chemotherapy. The treatment group, with 488 cases in total, took 150mg of erlotinib daily. The control group (243 cases) took a placebo. The study showed:
Median survival rate: 6.7 months for the treatment group, 4.7 months for the control (P<0.001, hazard ratio HR=0.73)
1 year survival rate: 31.2% for the treatment group, 21.5% for the control
Median time of no progression: 9.9 weeks for the treatment group, 7.9 weeks for the control
Meanwhile, symptomatic improvement in the treatment group was more pronounced.
Based on the results of the BR21 study, several further phase III clinical trials were conducted. The TRIBUTE trial combined erlotinib with chemotherapy. The treatment group used chemotherapy (carboplatin + paclitaxel) + erlotinib, while the control used the same chemotherapy alone, with a total of 1,059 late-stage NSCLC patients. The effectiveness of the treatment group was 21.5%, and the control group 19.3%; median survival times were 10.8 and 10.6 months, respectively, and the times of tumor progression (TTP) were 5.1 and 5.0 months. Meanwhile, TALENT trials, with 1,172 NSCLC patients, also investigated the effects of adding erlotinib to chemotherapy (gemcitabine + cisplatin), and also failed to show that erlotinib significantly increased its effects.
Chemical PropertiesOff-White Solid
UsesSelective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic
UsesErlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
UsesErlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Phase 3.
Erlotinib hydrochloride Preparation Products And Raw materials
Tag:Erlotinib hydrochloride(183319-69-9) Related Product Information
Erlotinib Triethylamine (Trifluoromethoxy)benzene Anisole Topotecan hydrochloride Guaiacol Bis(2-ethylhexyl)amine Ethoxyquin Triethanolamine Ethoxyethyne 4-Methoxyphenol ERLOTINIB-D6, HYDROCHLORIDE SALT Desmethyl Erlotinib Acetate ERLOTINIB MESYLATE Erlotinib hydrochloride Nilotinib Ethoxyamine hydrochloride Anisic aldehyde